Stem cell treatment of degenerative eye disease

Ben Mead*, Martin Berry, Ann Logan, Robert A.H. Scott, Wendy Leadbeater, Ben A. Scheven

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Stem cell therapies are being explored extensively as treatments for degenerative eye disease, either for replacing lost neurons, restoring neural circuits or, based on more recent evidence, as paracrine-mediated therapies in which stem cell-derived trophic factors protect compromised endogenous retinal neurons from death and induce the growth of new connections. Retinal progenitor phenotypes induced from embryonic stem cells/induced pluripotent stem cells (ESCs/iPSCs) and endogenous retinal stem cells may replace lost photoreceptors and retinal pigment epithelial (RPE) cells and restore vision in the diseased eye, whereas treatment of injured retinal ganglion cells (RGCs) has so far been reliant on mesenchymal stem cells (MSC). Here, we review the properties of non-retinal-derived adult stem cells, in particular neural stem cells (NSCs), MSC derived from bone marrow (BMSC), adipose tissues (ADSC) and dental pulp (DPSC), together with ESC/iPSC and discuss and compare their potential advantages as therapies designed to provide trophic support, repair and replacement of retinal neurons, RPE and glia in degenerative retinal diseases. We conclude that ESCs/iPSCs have the potential to replace lost retinal cells, whereas MSC may be a useful source of paracrine factors that protect RGC and stimulate regeneration of their axons in the optic nerve in degenerate eye disease. NSC may have potential as both a source of replacement cells and also as mediators of paracrine treatment.

Original languageEnglish
Pages (from-to)243-257
Number of pages15
JournalStem cell research
Volume14
Issue number3
DOIs
Publication statusPublished - 1 May 2015

Fingerprint

Eye Diseases
Stem Cells
Induced Pluripotent Stem Cells
Embryonic Stem Cells
Mesenchymal Stromal Cells
Retinal Neurons
Retinal Pigments
Neural Stem Cells
Retinal Ganglion Cells
Therapeutics
Retinal Diseases
Dental Pulp
Adult Stem Cells
Optic Nerve
Cell- and Tissue-Based Therapy
Neuroglia
Axons
Adipose Tissue
Regeneration
Bone Marrow

Bibliographical note

© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license(http://creativecommons.org/licenses/by/4.0/

Cite this

Mead, B., Berry, M., Logan, A., Scott, R. A. H., Leadbeater, W., & Scheven, B. A. (2015). Stem cell treatment of degenerative eye disease. Stem cell research, 14(3), 243-257. https://doi.org/10.1016/j.scr.2015.02.003
Mead, Ben ; Berry, Martin ; Logan, Ann ; Scott, Robert A.H. ; Leadbeater, Wendy ; Scheven, Ben A. / Stem cell treatment of degenerative eye disease. In: Stem cell research. 2015 ; Vol. 14, No. 3. pp. 243-257.
@article{20dd77de091a4d3496fe00030aca28ed,
title = "Stem cell treatment of degenerative eye disease",
abstract = "Stem cell therapies are being explored extensively as treatments for degenerative eye disease, either for replacing lost neurons, restoring neural circuits or, based on more recent evidence, as paracrine-mediated therapies in which stem cell-derived trophic factors protect compromised endogenous retinal neurons from death and induce the growth of new connections. Retinal progenitor phenotypes induced from embryonic stem cells/induced pluripotent stem cells (ESCs/iPSCs) and endogenous retinal stem cells may replace lost photoreceptors and retinal pigment epithelial (RPE) cells and restore vision in the diseased eye, whereas treatment of injured retinal ganglion cells (RGCs) has so far been reliant on mesenchymal stem cells (MSC). Here, we review the properties of non-retinal-derived adult stem cells, in particular neural stem cells (NSCs), MSC derived from bone marrow (BMSC), adipose tissues (ADSC) and dental pulp (DPSC), together with ESC/iPSC and discuss and compare their potential advantages as therapies designed to provide trophic support, repair and replacement of retinal neurons, RPE and glia in degenerative retinal diseases. We conclude that ESCs/iPSCs have the potential to replace lost retinal cells, whereas MSC may be a useful source of paracrine factors that protect RGC and stimulate regeneration of their axons in the optic nerve in degenerate eye disease. NSC may have potential as both a source of replacement cells and also as mediators of paracrine treatment.",
author = "Ben Mead and Martin Berry and Ann Logan and Scott, {Robert A.H.} and Wendy Leadbeater and Scheven, {Ben A.}",
note = "{\circledC} 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license(http://creativecommons.org/licenses/by/4.0/",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.scr.2015.02.003",
language = "English",
volume = "14",
pages = "243--257",
journal = "Stem cell research",
issn = "1873-5061",
publisher = "Elsevier",
number = "3",

}

Mead, B, Berry, M, Logan, A, Scott, RAH, Leadbeater, W & Scheven, BA 2015, 'Stem cell treatment of degenerative eye disease', Stem cell research, vol. 14, no. 3, pp. 243-257. https://doi.org/10.1016/j.scr.2015.02.003

Stem cell treatment of degenerative eye disease. / Mead, Ben; Berry, Martin; Logan, Ann; Scott, Robert A.H.; Leadbeater, Wendy; Scheven, Ben A.

In: Stem cell research, Vol. 14, No. 3, 01.05.2015, p. 243-257.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Stem cell treatment of degenerative eye disease

AU - Mead, Ben

AU - Berry, Martin

AU - Logan, Ann

AU - Scott, Robert A.H.

AU - Leadbeater, Wendy

AU - Scheven, Ben A.

N1 - © 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license(http://creativecommons.org/licenses/by/4.0/

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Stem cell therapies are being explored extensively as treatments for degenerative eye disease, either for replacing lost neurons, restoring neural circuits or, based on more recent evidence, as paracrine-mediated therapies in which stem cell-derived trophic factors protect compromised endogenous retinal neurons from death and induce the growth of new connections. Retinal progenitor phenotypes induced from embryonic stem cells/induced pluripotent stem cells (ESCs/iPSCs) and endogenous retinal stem cells may replace lost photoreceptors and retinal pigment epithelial (RPE) cells and restore vision in the diseased eye, whereas treatment of injured retinal ganglion cells (RGCs) has so far been reliant on mesenchymal stem cells (MSC). Here, we review the properties of non-retinal-derived adult stem cells, in particular neural stem cells (NSCs), MSC derived from bone marrow (BMSC), adipose tissues (ADSC) and dental pulp (DPSC), together with ESC/iPSC and discuss and compare their potential advantages as therapies designed to provide trophic support, repair and replacement of retinal neurons, RPE and glia in degenerative retinal diseases. We conclude that ESCs/iPSCs have the potential to replace lost retinal cells, whereas MSC may be a useful source of paracrine factors that protect RGC and stimulate regeneration of their axons in the optic nerve in degenerate eye disease. NSC may have potential as both a source of replacement cells and also as mediators of paracrine treatment.

AB - Stem cell therapies are being explored extensively as treatments for degenerative eye disease, either for replacing lost neurons, restoring neural circuits or, based on more recent evidence, as paracrine-mediated therapies in which stem cell-derived trophic factors protect compromised endogenous retinal neurons from death and induce the growth of new connections. Retinal progenitor phenotypes induced from embryonic stem cells/induced pluripotent stem cells (ESCs/iPSCs) and endogenous retinal stem cells may replace lost photoreceptors and retinal pigment epithelial (RPE) cells and restore vision in the diseased eye, whereas treatment of injured retinal ganglion cells (RGCs) has so far been reliant on mesenchymal stem cells (MSC). Here, we review the properties of non-retinal-derived adult stem cells, in particular neural stem cells (NSCs), MSC derived from bone marrow (BMSC), adipose tissues (ADSC) and dental pulp (DPSC), together with ESC/iPSC and discuss and compare their potential advantages as therapies designed to provide trophic support, repair and replacement of retinal neurons, RPE and glia in degenerative retinal diseases. We conclude that ESCs/iPSCs have the potential to replace lost retinal cells, whereas MSC may be a useful source of paracrine factors that protect RGC and stimulate regeneration of their axons in the optic nerve in degenerate eye disease. NSC may have potential as both a source of replacement cells and also as mediators of paracrine treatment.

UR - http://www.scopus.com/inward/record.url?scp=84924267865&partnerID=8YFLogxK

UR - https://www.sciencedirect.com/science/article/pii/S1873506115000306?via%3Dihub

U2 - 10.1016/j.scr.2015.02.003

DO - 10.1016/j.scr.2015.02.003

M3 - Review article

C2 - 25752437

AN - SCOPUS:84924267865

VL - 14

SP - 243

EP - 257

JO - Stem cell research

JF - Stem cell research

SN - 1873-5061

IS - 3

ER -